Why, When, and How? Optimising the Management of Patients with Severe Eosinophilic Asthma - European Medical Journal

Why, When, and How? Optimising the Management of Patients with Severe Eosinophilic Asthma

Download PDF
Ian Pavord1
Roland Buhl,2 Richard W. Costello,3 Mario Castro4

Prof Pavord has received speaker’s honoraria from AstraZeneca, Boehringer Ingelheim, Aerocrine, Respivert, Teva, and GSK; and advisory panel fees from Almirall, AstraZeneca, Boehringer Ingelheim, GSK, MSD, Schering-Plough, Novartis, Dey, and Napp. Prof Pavord has also received sponsorship honoraria from Boehringer Ingelheim, GSK, AstraZeneca, and Napp. Prof Buhl has received speaker/ consulting honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Roche, and Teva, and has received research support from Boehringer Ingelheim, GSK, Novartis, and Roche. Prof Costello is a speaker and advisory board member to Aerogen, Boehringer Ingelheim, GSK, Novartis, and Teva, and has received grant support from Aeorogen, Vitalograph, and GSK. Prof Costello has an active patent on use of acoustic analysis to assess inhaler technique of use. Prof Castro has received royalties from Elsevier, speaker fees from Boeringer Ingelheim, Boston Scientific, Genentech, and Teva and has received consulting fees from AstraZeneca, Boston Scientific, Holaira, NeoStem, Neutronic, Novartis, Roche, Sanofi Aventis, Teva, and Therabron. Prof Castro has also received funding from AsthmaNet, the American Lung Association, Severe Asthma Research Programme, Amgen, Boehringer Ingelheim, Genentech, Gilead, GSK, Invion, Johnson & Johnson, Medimmune/AstraZeneca, Novartis, Pfizer, Sanofi Aventis, Teva, and Vectura.


Writing assistance was provided by Mia Cahill of ApotheCom.


The publication of this article and the symposium at the International Congress of the European Respiratory Society (ERS) were funded by Teva Pharmaceuticals B.V. The views and opinions expressed are those of the authors and not necessarily Teva Pharmaceuticals B.V. or the ERS.

EMJ Respir. ;4[1]:51-59. DOI/10.33590/emjrespir/10311829. https://doi.org/10.33590/emjrespir/10311829.
ERS 2016, European Respiratory Society

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The main objectives of this symposium were to explore the challenges faced when treating patients with severe eosinophilic asthma, to evaluate the key clinical assessments that are available for early disease recognition, and to discuss the latest personalised treatment options that could shape future management strategies. Prof Ian Pavord opened the symposium by introducing uncontrolled severe asthma, focussing on the challenges and unmet needs of patients. Prof Buhl then delved into the basics of eosinophilic asthma from a molecular and physiological point of view, discussing the clinical relevance and characterisation of eosinophilic patients. Prof Costello focussed on the key clinical assessments (diagnosis, adherence, and phenotyping) and management of patients. Prof Castro summarised the latest evidence from studies of mepolizumab, benralizumab, reslizumab, anti-interleukin (IL)-4, and anti-IL-13 therapies, and how this relates to clinical practice.

Please view the full content in the PDF above. 

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now